Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Breast Cancer | Primary research

PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells

Authors: Jia Cao, Xi Wang, Danni Wang, Rong Ma, Xiaohan Li, Huimin Feng, Jia Wang, Shihai Liu, Libin Wang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Breast cancer is one of the most common malignancy among females from the worldwide cancer incidence statistics. Peroxisome gamma coactivator-1β (PGC-1β) has long been identified to be involved in this type of tumorigenesis. However, the mechanisms of PGC-1β in human breast cancer have not been fully understood and the function requires to be further elucidated.

Methods

mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively. To further visualize the expression and localization of PGC-1β and FOXA2, immunochemistry and immunofluorescence staining methods were employed. The effect of PGC-1β and FOXA2 on cell proliferation and migration were evaluated by CCK8, clone formation, transwell and wound-healing assays, which has been done either with stable PGC-1β knockdown or FOXA2 overexpression in vitro. Xenografts model of nude mice were used to evaluate tumor growth in vivo. In addition, proteins expression of the PI3K-AKT-mTOR signaling pathway involved in the regulation of breast cancer were detected by Western Blotting.

Results

Our results showed that PGC-1β was upregulated and FOXA2 was downregulated in breast cancer tissues and cell lines. These two proteins can be interacted with each other to form the complex. Also, we found the combination of PGC-1β interference with FOXA2 overexpression significantly inhibited cell proliferation and migration in vitro as well as tumor growth in vivo. We further identified that PGC-1β and FOXA2 strongly correlated with the PI3K-AKT-mTOR signaling pathway, and they exerted their biological functions by activating this pathway.

Conclusions

We demonstrated that downregulation of PGC-1β combined with overexpression of FOXA2 obviously inhibited the function of breast cancer cells through regulating the PI3K-AKT-mTOR pathway.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.PubMed
2.
Zeng Y, Sang J. Five zinc finger protein 350 single nucleotide polymorphisms and the risks of breast cancer: a meta-analysis. Oncotarget. 2017;8(63):107273–82.PubMedPubMedCentralCrossRef
3.
Hamurcu Z, Delibaşı N, Geçene S, Şener E, Dönmez-Altuntaş H, Özkul Y, Canatan H, Ozpolat B. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2017;144(3):415–30.PubMedCrossRef
4.
Lin J, Handschin C, Spiegelman B. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005;1(6):361–70.PubMedCrossRef
5.
Ahmad S, Valli H, Salvage S, Grace A, Jeevaratnam K, Huang C. Age-dependent electrocardiographic changes in Pgc-1β deficient murine hearts. Clin Exp Pharmacol Physiol. 2018;45(2):174–86.PubMedCrossRef
6.
Liu C, Lin J. PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin (Shanghai). 2011;43(4):248–57.CrossRef
7.
Schilling J, Kelly D. The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51(4):578–83.PubMedCrossRef
8.
Riehle C, Wende A, Zaha V, Pires K, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira A, et al. PGC-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res. 2011;109(7):783–93.PubMedPubMedCentralCrossRef
9.
Lehman J, Barger P, Kovacs A, Saffitz J, Medeiros D, Kelly D. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106(7):847–56.PubMedPubMedCentralCrossRef
10.
Lin J, Wu H, Tarr P, Zhang C, Wu Z, Boss O, Michael L, Puigserver P, Isotani E, Olson E, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797–801.PubMedCrossRef
11.
Lee S, Leone T, Rogosa L, Rumsey J, Ayala J, Coen P, Fitts R, Vega R, Kelly D. Skeletal muscle PGC-1β signaling is sufficient to drive an endurance exercise phenotype and to counteract components of detraining in mice. Am J Physiol Endocrinol Metab. 2017;312(5):E394–406.PubMedPubMedCentralCrossRef
12.
Huss J, Torra I, Staels B, Giguère V, Kelly D. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. 2004;24(20):9079–91.PubMedPubMedCentralCrossRef
13.
Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu P, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005;1(4):259–71.PubMedCrossRef
14.
Andersen G, Wegner L, Yanagisawa K, Rose C, Lin J, Glümer C, Drivsholm T, Borch-Johnsen K, Jørgensen T, Hansen T, et al. Evidence of an association between genetic variation of the coactivator PGC-1beta and obesity. J Med Genet. 2005;42(5):402–7.PubMedPubMedCentralCrossRef
15.
Enguix N, Pardo R, González A, López V, Simó R, Kralli A, Villena J. Mice lacking PGC-1β in adipose tissues reveal a dissociation between mitochondrial dysfunction and insulin resistance. Mol Metab. 2013;2(3):215–26.PubMedPubMedCentralCrossRef
16.
Piccinin E, Peres C, Bellafante E, Ducheix S, Pinto C, Villani G, Moschetta A. Hepatic PPARγ coactivator 1β drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma progression. Hepatology (Baltimore, MD). 2018;67(3):884–98.CrossRef
17.
Victorino V, Barroso W, Assunção A, Cury V, Jeremias I, Petroni R, Chausse B, Ariga S, Herrera A, Panis C, et al. PGC-1β regulates HER2-overexpressing breast cancer cells proliferation by metabolic and redox pathways. Tumour Biol. 2016;37(5):6035–44.PubMedCrossRef
18.
Wang L, Liu Q, Li F, Qiu J, Fan H, Ma H, Zhu Y, Wu L, Han X, Yang Z, et al. Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. Oncol Rep. 2013;30(4):1631–8.PubMedCrossRef
19.
Mfopou J, Geeraerts M, Dejene R, Van Langenhoven S, Aberkane A, Van Grunsven L, Bouwens L. Efficient definitive endoderm induction from mouse embryonic stem cell adherent cultures: a rapid screening model for differentiation studies. Stem Cell Res. 2014;12(1):166–77.PubMedCrossRef
20.
Kaestner K, Knochel W, Martinez D. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000;14(2):142–6.PubMed
21.
Bonnavion R, Teinturier R, Gherardi S, Leteurtre E, Yu R, Cordier-Bussat M, Du R, Pattou F, Vantyghem M, Bertolino P, et al. Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas. J Pathol. 2017;242(1):90–101.PubMedCrossRef
22.
Ozaki T, Matsubara T, Seo D, Okamoto M, Nagashima K, Sasaki Y, Hayase S, Murata T, Liao X, Hanson J, et al. Thyroid regeneration: characterization of clear cells after partial thyroidectomy. Endocrinology. 2012;153(5):2514–25.PubMedPubMedCentralCrossRef
23.
Chu G, Zhau H, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson M, You S, Kim J, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 2014;21(2):311–26.PubMedPubMedCentralCrossRef
24.
Cao L, Gibson J, Miyamoto S, Sail V, Verma R, Rosenberg D, Nelson C, Giardina C. Intestinal lineage commitment of embryonic stem cells. Differentiation. 2011;81(1):1–10.PubMedCrossRef
25.
Kaestner K. The making of the liver: developmental competence in foregut endoderm and induction of the hepatogenic program. Cell Cycle. 2005;4(9):1146–8.PubMedCrossRef
26.
Gao N, LeLay J, Vatamaniuk M, Rieck S, Friedman J, Kaestner K. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 2008;22(24):3435–48.PubMedPubMedCentralCrossRef
27.
Zhang Z, Yang C, Gao W, Chen T, Qian T, Hu J, Tan Y. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett. 2015;361(2):240–50.PubMedCrossRef
28.
Perez-Balaguer A, Ortiz-Martínez F, García-Martínez A, Pomares-Navarro C, Lerma E, Peiró G. FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. Breast Cancer Res Treat. 2015;153(2):465–74.PubMedCrossRef
29.
Myatt S, Lam E. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7(11):847–59.PubMedCrossRef
30.
Friedman J, Kaestner K. The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci. 2006;63(19–20):2317–28.PubMedCrossRef
31.
32.
Song Y, Washington M, Crawford H. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010;70(5):2115–25.PubMedPubMedCentralCrossRef
33.
Tu M, Pan Y, Qiu J, Kim E, Yu A. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 2016;7(29):45547–61.PubMedPubMedCentralCrossRef
34.
35.
Deblois G, St-Pierre J, Giguère V. The PGC-1/ERR signaling axis in cancer. Oncogene. 2013;32(30):3483–90.PubMedCrossRef
36.
37.
Kumazoe M, Takai M, Hiroi S, Takeuchi C, Kadomatsu M, Nojiri T, Onda H, Bae J, Huang Y, Takamatsu K, et al. The FOXO3/PGC-1beta signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. J Biol Chem. 2017;292(26):10813–23.PubMedPubMedCentralCrossRef
38.
Bellafante E, Morgano A, Salvatore L, Murzilli S, Di Tullio G, D’Orazio A, Latorre D, Villani G, Moschetta A. PGC-1β promotes enterocyte lifespan and tumorigenesis in the intestine. In: Proceedings of the National Academy of Sciences of the United States of America. 2014;111(42):E4523–31.CrossRef
39.
Sekiya T, Muthurajan U, Luger K, Tulin A, Zaret K. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev. 2009;23(7):804–9.PubMedPubMedCentralCrossRef
40.
Li C, Gocheva V, Oudin M, Bhutkar A, Wang S, Date S, Ng S, Whittaker C, Bronson R, Snyder E, et al. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev. 2015;29(17):1850–62.PubMedPubMedCentralCrossRef
41.
Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 2006;3(2):99–110.PubMedCrossRef
42.
43.
Lau M, Leung P. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 2012;326(2):191–8.PubMedCrossRef
44.
Liu X, Jiang Q, Liu H, Luo S. Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells. Biol Res. 2019;52(1):7.PubMedPubMedCentralCrossRef
45.
Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good RB, et al. The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun. 2019;10(1):6.PubMedPubMedCentralCrossRef
Metadata
Title
PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells
Authors
Jia Cao
Xi Wang
Danni Wang
Rong Ma
Xiaohan Li
Huimin Feng
Jia Wang
Shihai Liu
Libin Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0810-5

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma

Review

Melatonin and non-small cell lung cancer: new insights into signaling pathways

Primary research

SWAP-70 promotes glioblastoma cellular migration and invasion by regulating the expression of CD44s

Primary research

Metabolic characteristics revealing cell differentiation of nasopharyngeal carcinoma by combining NMR spectroscopy with Raman spectroscopy

Review

CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target

Correction

Correction to: Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits